MétaCan
Menu
Back to cohort
Record W2783123696 · doi:10.1002/hep.29771

Treatment of acute hepatitis C virus is cost‐effective but at what price?

2018· letter· en· W2783123696 on OpenAlexaff
Stephen E. Congly, Samuel S. Lee

Bibliographic record

VenueHepatology · 2018
Typeletter
Languageen
FieldMedicine
TopicHepatitis C virus research
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsMedicineJaundiceAsymptomaticTransmission (telecommunications)Intensive care medicineHepatitis C virusInternal medicineImmunologyVirus

Abstract

fetched live from OpenAlex

Potential conflict of interest: Nothing to report. TO THE EDITOR: Bethea et al.1 provide an interesting study modeling that early treatment of acute hepatitis C virus (HCV) is cost‐effective and potentially cost‐saving in a group at high risk of transmission rather than waiting until chronicity is confirmed in 6 months' time. Current American Association for the Study of Liver Diseases guidelines2 recommend against treating acute HCV given a spontaneous clearance rate of approximately 28%.3 Acute HCV is largely asymptomatic, so identified cases will typically have symptoms, particularly jaundice; spontaneous clearance may approach 50% in patients with jaundice.4 Initial data suggest that shorter treatment courses are efficacious for acute HCV, although the trials are small and only genotype 1 was studied. The reduced length of treatment is the key determinant of the differences between the strategies cost‐wise in this model; as more patients spontaneously clear, the cost‐effectiveness of treating acute HCV decreases. Although this study suggests that early treatment is cost‐effective in patients at low risk of transmission and cost‐saving for patients at high risk of transmission, implementing an acute treatment strategy carries the risk of significant unnecessary costs for patients who would otherwise spontaneously clear the infection. Assuming a spontaneous clearance rate of 28% and 34,000 acute HCV infections in the United States annually, 9,520 people would receive potentially unneeded therapy. As such, between $4,598,160 and $79,225,440 (2016 USD) of unnecessary spending would be required depending on whether acute HCV required 6 or 8 weeks of treatment versus 8 weeks for chronic HCV. For patients at high risk of transmission, if both strategies require an 8‐week treatment duration, there could be an additional cost of $27,398,560, while if acute HCV could be treated with a shorter duration, early treatment would be cost‐saving due to the reduced risk of transmission. The authors provide important data for policy makers and clinicians to consider; however, we would caution against any major changes for patients at low risk of transmission until further data on the efficacy of direct‐acting antiviral agents are available for all genotypes given the significant expense for patients who would spontaneously clear. For patients at high risk of transmission, the added cost of treating individuals who would otherwise spontaneously clear may be of value given reduced transmission rates if acute HCV requires similar treatment duration to chronic HCV. If a shorter duration is possible, early treatment of high‐risk patients with acute HCV would be good public health policy given that it is cost‐saving.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Research integrity, Insufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.418
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0060.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.344
Teacher spread0.308 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueHepatologySame topicHepatitis C virus researchFrench-language works237,207